Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society ...
In Phase 1 studies, cudetaxestat displayed low potential for drug-drug interactions when dosed with approved therapies for idiopathic pulmonary fibrosis (IPF) and other commonly used medications Cudetaxestat was well tolerated and showed no reports of …